Relationship and significance between anti-β2-glycoproteinI antibodies and platelet activation state in patients with ulcerative colitis

Table 1 Detection results of aβ₂GPI in patients among groups (A₄₉₂, mean ± SD)

Group	n	IgM	IgG
Active UC group	36	0.43 ± 0.13b	0.61 ± 0.13bd
Remittent UC group	20	0.38 ± 0.12b	0.50 ± 0.13b
Control group	25	0.20 ± 0.12	0.22 ± 0.14

^bP < 0.01 vs control group;

^dP < 0.01 vs remittent UC group.

Table 2 Positive expression rate for platelet activation marker in different groups of patients (%, mean ± SD)

Group	n	PAC-I	CD62P
Active UC group	36	30.6 ± 7.6bd	45.0 ± 8.8bd
Remittent UC group	20	19.6 ± 7.8b	31.9 ± 7.8b
Control group	25	6.3 ± 1.7	9.2 ± 2.7

^bP < 0.01 vs control group;

^dP < 0.01 vs remittent UC group.

Table 3 Correlation between aβ₂GPI, platelet activation marker and disease grades in 36 active UC patients

Grade	n	aβ2GPI 492 (IgG)	PAC-I positive rate (%)	CD62P positive rate (%)
Mild	19	0.64	31.8	48.7
Moderate	11	0.80	40.6	60.9
Severe	6	0.92	53.7	71.2
F		3.679	5.346	5.418
P		< 0.05	< 0.01	< 0.01